U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H23NO2.C6H8O7
Molecular Weight 453.4828
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHOHEPTAZINE CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCOC(=O)C1(CCCN(C)CC1)C2=CC=CC=C2

InChI

InChIKey=KCVHFFSPDODYOG-UHFFFAOYSA-N
InChI=1S/C16H23NO2.C6H8O7/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-6,8-9H,3,7,10-13H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI
Molecular Formula C16H23NO2
Molecular Weight 261.3593
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ethoheptazine is an analgesic, which belongs to the proheptazine group. It was used either alone (Zactane trade name) or in combination with meprobamate and aspirin (Equagesic) for the pain relief in patients with headache or musculoskeletal disorders. Currently all mediactions containing ethoheptazine are withdrawn from the market. The exact target of ethoheptazine is unknow, but it is believed that it may have modulatory effect on opioid receptors.

CNS Activity

Approval Year

1957
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
828
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
EQUAGESIC

Approved Use

Equagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache.
Primary
Approved
8429
EQUAGESIC

Approved Use

Equagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache.
Doses

Doses

DosePopulationAdverse events​
100 mg 6 times / day multiple, oral
Recommended
Dose: 100 mg, 6 times / day
Route: oral
Route: multiple
Dose: 100 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13469802
Page: p.416
unhealthy
n = 83
Health Status: unhealthy
Condition: Pain
Sex: F
Population Size: 83
Sources:
https://pubmed.ncbi.nlm.nih.gov/13469802
Page: p.416
Sources:
https://pubmed.ncbi.nlm.nih.gov/13469802
Page: p.416
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY571131
https://www.001chemical.com/chem/77-15-6
ABI Chem
AC1L1MLL
AK Scientific
2032AC
AK Scientific, Inc. (AKSCI)
2032AC
http://www.aksci.com/item_detail.php?cat=2032AC
AN PharmaTech
AN-5629
Ambinter
Amb22002573
http://www.ambinter.com/reference/22002573
Aurora Fine Chemicals LLC
A30.257.838
http://online.aurorafinechemicals.com/info?ID=A30.257.838
BLD Pharm
BD127693
http://www.bldpharm.com/products/77-15-6.html
BePharm Ltd.
B127693
ChemMol
49400380
http://www.chemmol.com/chemmol/49400380.html
ChemMol
99151439
http://www.chemmol.com/chemmol/99151439.html
ChemTik
CTK6F4564
Chemhere
Achem589535
Chemieliva Pharmaceutical Co., Ltd
PBCM0825114
Compound Cloud
23165
Compound Cloud
6469
Molcore
MC571131
https://www.molcore.com/product/77-15-6
NCI Plated 2007
400484
Norris Pharm
NSZB-A224720
NovoSeek
6469
Oxchem Corporation
AX8127693
Smolecule
S600803
https://www.smolecule.com/products/s600803
THE BioTek
bt-433592
https://www.thebiotek.com/product/others/bt-433592
Toronto Research Chemicals
E678280
ZINC
ZINC000000000268
http://zinc15.docking.org/substances/ZINC000000000268
ZINC
ZINC000001593302
http://zinc15.docking.org/substances/ZINC000001593302
PubMed

PubMed

TitleDatePubMed
Analgesic effectiveness of orally administered ethoheptazine in man.
1957 Oct
Methods in evaluating ethoheptazine and ethoheptazine combined with aspirin.
1958 Apr 12
Clinical comparison of ethoheptazine and aspirin with other analgesic combinations.
1961 Mar
Treatment of musculoskeletal pain and associated anxiety with an ethoheptazine-aspirin-meprobamate combination (equagesic): a controlled study.
1974 Sep
Effects of propoxyphene, ethoheptazine, and azabicyclane on schedule-controlled responding: attenuation by pentobarbital but not naloxone.
1979
Determination of ethoheptazine in human post mortem material.
1983 Oct 14
Fixed drug eruption masquerading as herpes simplex labialis.
1984 Sep 29
Mefenamic acid, chlormezanone-paracetamol, ethoheptazine-aspirin-meprobamate: a comparative study in acute low back pain.
1987 Feb
Patents

Patents

JP2005520783A
40

Sample Use Guides

In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:00:41 GMT 2023
Edited
by admin
on Fri Dec 15 15:00:41 GMT 2023
Record UNII
LXK8EE245D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHOHEPTAZINE CITRATE
JAN   MART.   MI   VANDF   WHO-DD  
Common Name English
ETHOHEPTAZINE CITRATE [MART.]
Common Name English
ETHOHEPTAZINE CITRATE [MI]
Common Name English
ETHYL HEXAHYDRO-1-METHYL-4-PHENYL-1H-AZEPINE-4-CARBOXYLATE CITRATE
Systematic Name English
ETHOHEPTAZINE CITRATE [JAN]
Common Name English
Ethoheptazine citrate [WHO-DD]
Common Name English
ETHOHEPTAZINE CITRATE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT001084
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
MERCK INDEX
m1138
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY Merck Index
CAS
6700-56-7
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
SMS_ID
100000087280
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
NCI_THESAURUS
C76841
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
RXCUI
235416
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
229-743-0
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
EVMPD
SUB02001MIG
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
ChEMBL
CHEMBL170797
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
PUBCHEM
23165
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
FDA UNII
LXK8EE245D
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
CAS
2085-42-9
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
ALTERNATIVE
EPA CompTox
DTXSID80943103
Created by admin on Fri Dec 15 15:00:41 GMT 2023 , Edited by admin on Fri Dec 15 15:00:41 GMT 2023
PRIMARY
Related Record Type Details
Structure of ANHYDROUS CITRIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ETHOHEPTAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966